Archive for March 30th, 2009
Back in the early 1970s a researcher in the employ of the U.S. Government National Institutes of Health (NIH) made a discovery. In a certain strain of laboratory rats he found a substance that not only made animals immune to getting arthritis, but also cured afflicted animals. The substance, originally extracted from ground up Swiss Albino Mice, is called cetylmyristoleate.
However, when the researcher reported his remarkable findings to his superiors in an attempt to secure funding for additional research, his request was mysteriously denied. Nevertheless, struggling along without authorization, he continued his studies and reported further successes. Strangely, not only were his requests for funding continuously denied, all of his accomplishments went completely unrecognized. Though they never said so directly, it was as though the NIH wanted him to abandon the project completely. Discouraged though he was, he still continued his research as best he could with absolutely no funding at all. When he retired about a decade later, since even the mere existence of his work went completely unacknowledged by the NIH, he took his discovery with him and continued the research on his own. And well he deserved to do so. Had he not, his discovery may never have come to light.
It has been reported that some time later, one by one he went to three different major pharmaceutical companies offering to share his discovery. One by one, his offers were
rejected – not for lack of effectiveness, but because the product was derived from natural sources it could not be patented in a way to hog all the profits. The companies couldn’t care less about the fact that it worked, only that they couldn’t protect it from being manufactured by some competing company. Nor did they express any interest in funding further research on the project.
One could also speculate on the likelihood that by making available a product that potentially reverses the arthritic process permanently, it would kill their annual multi-billion dollar sales of existing arthritis products – all of which must be taken repeatedly for the rest of the arthritis victims’ lives. Quite understandably, of course, the pharmaceutical companies love products that lead to a lifetime of repeat sales.
After its rejection by the pharmaceutical companies the project lay fallow for several years. No further attempts were made to explore its potential.
The chain of events that followed have never been made crystal clear. It has been reported that as some years passed, the researcher himself began to suffer terribly from arthritis and was receiving conventional medical therapy to treat it. It is important to note that despite the fact that he had explored the safety and effectiveness of his discovery on lower animals at the NIH, research had never reached the level of testing on higher animals. But once his arthritis reached excruciating extremes and his physician told him that he was beyond any effective help, the researcher decided to take a risk. He brewed up a batch of cetylmyristoleate at home and injected himself. Thus, he became the first person ever to receive the substance as a test of the discovery on human beings. We honour his courage.
It was a historic moment. He began to feel symptomatic relief the very next day, and soon he reached a point where he experienced total reversal of his arthritis. His doctor was astonished when he subsequently examined his patient and heard the whole story of the discovery.
The doctor was so impressed that he persuaded him to write an account of his research project. The doctor promised to help him get it published in the Journal of Pharmaceutical Sciences, hoping that the article might stimulate someone into continuing the exploration of the project. Then, early in 1995, a few months after the article appeared, that’s exactly what happened. The San Diego Clinic International Immunological Centre (SDC) embarked on a project to develop the discovery into a usable product.
But long before that, it seems that several years had intervened between the self-injection and the actual publication of the article. Meanwhile, it has been reported, even though the substance was provided quite informally to a couple hundred more arthritis victims with astounding success, there was no formal progress in research or development.
The journal article itself didn’t seem to stimulate much interest either. Perhaps that’s because it was only three pages long and dealt solely with mouse model studies. Besides, it was reporting on research that took place over twenty years before. Perhaps the readers thought there couldn’t be much value to something that had lain dormant so very long. Or maybe they thought there must have been more recent research that refuted the early findings. Nor did the article provoke questions about why it had been ignored by the NIH and how it came to buried for so
long – except in one instance.
*11\142\2*
read comments (0)
There are only a few distributors that offer legitimate CMO, using the same form I tested in my medical clinics, and have demonstrated to be effective in with my patients. Unfortunately, there are also many ineffective products fraudulently labelled “CMO” being foisted on unsuspecting arthritis victims. The authenticity of the genuine product was confirmed in a recent court decision. A Federal District Court awarded monetary damages to the manufacturer of the genuine product as a result of a case filed against one impostor. We devote a whole chapter later in this book to help you identify and avoid those counterfeit products. Preying on the public by producing, would you believe, worthless counterfeit CMO! So look for products using certified CMO, such as CMO Cerasomal-cis-9-cetylmyristoleate™ fatty acids. In some parts of the world, including parts of Europe, the authentic product is individually certified with a coded serial number unique to each bottle of the authenticated product.
*9\142\2*
From our work we have found that only CMO has corrective and restorative immunomodulatory properties for autoimmune diseases. Other so-called “immunomodulators” do not. They function primarily as immunosuppressants or immunostimulants. They are capable of only one principal action, either suppressing or stimulating immune function.
CMO, on the other hand, corrects autoimmune programs within the memory T-cells themselves rather than just temporarily suppressing or stimulating immune system activities. That is why a single CMO therapy program can correct memory T-cell faults without any need to continually apply the therapy or use any additional medication of any kind.
CMO is not an immunosuppressant, nor an immunostimulant. Nor is it a pharmaceutical. It is a naturally derived substance. Some practitioners have speculated that, in the case of arthritis for example, CMO merely acts upon pain receptors at the arthritic site. If that were so, CMO’s effects would not be so permanent. Furthermore, that theory cannot explain:
• how CMO lowers blood sedimentation rates in lupus patients,
• or how it reverses lung inflammation in emphysema,
• or how it lowers the need for insulin in diabetics,
• or how it reverses prostate inflammation,
• or how it relieves certain symptoms of multiple sclerosis,
• or how it corrects Crohn’s disease,
• or how it reverses fibromyalgia
• or how it lowers high blood pressure yet elevates low blood pressure,
• or how it benefits virtually any ailment with autoimmune components.
Obviously, CMO is a general remedial immunomodulator that acts upon the memory T-cells which control the autoimmune processes within our bodies. Those who speculate otherwise have misunderstood the physiological actions of CMO within the body.
It is also important to understand that CMO acts only upon memory T-cells and does not inhibit the activities of any of the several other types of T-cells or protective immune system agents that are responsible for combating invading microorganisms or intrusive substances.
Unlike the immunosuppressants commonly used to try to temporarily control the symptoms of autoimmune diseases, CMO does not leave the body vulnerable to attack by disease-causing agents. Nor does it inhibit the body’s resistance to tumor formation, as do the dangerous tumor necrosis factor (TNF) suppressants of some new arthritis drugs
*7\142\2*
Now it might be useful to explain autoimmune processes in genera] with greater clarity. A keen understanding can be very useful in everyday life. Let’s start with a simple step-by-step explanation of the arthritic process because that applies to virtually every human autoimmune process and virtually all diseases with autoimmune factors.
The Autoimmune-Arthritic Process – Step-By-Step
The following is an overview of the autoimmune-arthritic process. The process is explained in eleven steps. It all starts with initiation of altered autoimmune system function.
1. First, infection, trauma, or excessive wear affects the joints. The usual infections are rheumatic fever, flu, or bacteria. Traumas include events such as, jolts or injuries from auto wrecks, falls, sports injuries, jogging, etc. Excessive joint wear comes from being overweight, or from repetitive use of keyboards, jackhammers, knitting needles, screwdrivers etc.
2. The effects of #1 cause damaged or infected cartilage particles to be dislodged from their normal site. This happens regardless of whether it’s rheumatoid, reactive, or osteoarthritis.
3. Macrophages of the immune system begin a cleanup of these dislodged cartilage particles. That’s a normal part of their job.
4. Macrophages report their activities to dormant memory T-cells, which are the commanding “generals” of the immune system that direct the activities of other immune cells.
5. The reports from the macrophages activate the dormant memory T-cells, then develop aggressive anti-cartilage cleanup programs. Unfortunately, these programs do not distinguish between healthy and damaged cartilage.
7. The increased memory T-cell population continues to stimulate more macrophage activity, and the self-perpetuating cycle of cartilage destruction expands. Because the memory T-cell programs don’t limit macrophage activity to damaged cartilage only, destruction of healthy cartilage also occurs. It has now developed into a destructive autoimmune process. But, until sufficient cartilage has been destroyed, symptoms are not evident. The individual is unaware that the destructive process is occurring.
8. The initiating factor (infection, trauma, weight) taking place in # 1, may have disappeared many months or years ago, but the destructive autoimmune process remains active. It is self perpetuating and no longer dependent upon the initiating factor. When this happens it has become a pure autoimmune disease.
9. The cycle is compounded by the fact that the mechanism which should deactivate certain memory T-cells (those that have completed their mission) fails to function. The constant macrophage re-stimulation of the memory T-cells keeps them active. The memory T-cells also re-stimulate each other. So now there is an overabundance of memory T-cells propelling macrophage cartilage destruction. The immune system is now totally out of control and massive cartilage destruction often begins. Early symptoms of pain and inflammation often appear.
10. Cartilage destruction accelerates. The cycle reaches an explosive critical mass. Macrophages are now scouring the body to find and destroy any cartilage anywhere it can be found. Symptoms become more severe. Pain, inflammation, and joint deformity intensify at old sites and now appear at new sites as they suffer macrophage attacks. Any or all joints may be affected, including the spine.
11. Symptoms of pain, stiffness, swelling, nodules, and deformation often reach intolerable and crippling levels-especially as joint cartilage disappears and bone-on-bone erosion occurs. Conventional arthritis medications also take their toll on the liver, kidneys, and heart. Normal life span is often shortened by ten or twenty years not only from the ravages of arthritis, but from the side effects of both prescription and over-the-counter medications as well.
By deactivating the memory T-cells, CMO intervention (the sooner the better) can stop the autoimmune process at any point.
Current medical dogma holds that only rheumatoid arthritis is an autoimmune disease. On the contrary, the above explanation makes it evident that osteoarthritis is an autoimmune disease as well. The sooner the medical community accepts that fact, the better they may be able to treat their arthritis patients effectively.
*5\142\2*
In the case of arthritis, once macrophages have dealt with some particles of cartilage they develop a chemical message that’s passed on to the memory T-cells. If there’s only one message of that type, the memory T-cells ignore it, but if that message is repeated then they develop a program instructing more and more macrophages to dispose of the cartilage. Unfortunately, that message doesn’t (or maybe can’t) distinguish between healthy or unhealthy cartilage. So the destructive onslaught against your joints begins.
It seems that it is the inflammatory process itself that initiates the arthritic process, regardless of what triggers the inflammation. In other words, the arthritic process can start whether the particles of cartilage result from an attack by certain pathogenic micro-organisms (leading to rheumatoid arthritis) or by a trauma (developing into osteoarthritis)!
In either case, rheumatoid or osteoarthritis, it results in a vicious cycle. As more macrophages bring back messages to the memory T-cells, more and more T-cells develop programs that direct attacks against the cartilage and arthritis continues to get progressively worse. You almost never hear of arthritis getting better. Now you’ve learned why.
*3\142\2*